Global X Management Co. LLC increased its stake in Boston Scientific Corporation (NYSE:BSX) by 29.2% during the second quarter, Holdings Channel reports. The firm owned 24,843 shares of the medical equipment provider’s stock after buying an additional 5,610 shares during the period. Global X Management Co. LLC’s holdings in Boston Scientific Corporation were worth $689,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Bronfman E.L. Rothschild L.P. raised its position in Boston Scientific Corporation by 7.2% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 5,041 shares of the medical equipment provider’s stock valued at $125,000 after buying an additional 338 shares during the period. Guardian Life Insurance Co. of America raised its position in Boston Scientific Corporation by 0.9% in the first quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock valued at $131,000 after buying an additional 49 shares during the period. Parametrica Management Ltd bought a new position in Boston Scientific Corporation during the second quarter valued at $219,000. Commerce Bank bought a new position in Boston Scientific Corporation during the first quarter valued at $207,000. Finally, Gilbert & Cook Inc. bought a new position in Boston Scientific Corporation during the second quarter valued at $239,000. 91.62% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Boston Scientific Corporation (NYSE:BSX) opened at 26.47 on Wednesday. The stock’s 50 day moving average price is $27.26 and its 200-day moving average price is $26.12. The company has a market capitalization of $36.32 billion, a P/E ratio of 47.35 and a beta of 1.09. Boston Scientific Corporation has a 52-week low of $19.67 and a 52-week high of $28.51.

Boston Scientific Corporation (NYSE:BSX) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same period last year, the business posted $0.27 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. On average, equities analysts expect that Boston Scientific Corporation will post $1.26 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Boston Scientific Corporation (BSX) Stake Boosted by Global X Management Co. LLC” was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/boston-scientific-corporation-bsx-stake-boosted-by-global-x-management-co-llc/1493548.html.

A number of research analysts recently weighed in on BSX shares. Cowen and Company reissued a “buy” rating and set a $32.00 target price (up from $31.00) on shares of Boston Scientific Corporation in a report on Friday, July 28th. Zacks Investment Research raised Boston Scientific Corporation from a “sell” rating to a “hold” rating in a report on Monday, July 31st. UBS AG reissued a “buy” rating and set a $31.00 target price (up from $30.00) on shares of Boston Scientific Corporation in a report on Tuesday, August 1st. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Boston Scientific Corporation in a report on Wednesday, August 9th. Finally, J P Morgan Chase & Co reissued an “overweight” rating and set a $31.00 target price (up from $27.00) on shares of Boston Scientific Corporation in a report on Wednesday, June 28th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $30.06.

In other news, SVP Wendy Carruthers sold 12,433 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $26.75, for a total value of $332,582.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP John Bradley Sorenson sold 7,900 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $26.37, for a total value of $208,323.00. Following the completion of the transaction, the senior vice president now directly owns 21,680 shares of the company’s stock, valued at $571,701.60. The disclosure for this sale can be found here. Insiders sold 207,625 shares of company stock valued at $5,686,383 over the last three months. Company insiders own 0.74% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.